Nov 6, 2012 by Dave Williamson and Brenton FlynnWhy Investors Are Voting Against Novo NordiskIt may be a rough FDA advisory committee.
Nov 6, 2012 by Dave Williamson and Brenton FlynnWhy Investors Are Voting Against Express ScriptsNegative comments on the conference call spurred a sell-off.
Nov 6, 2012 by Dave Williamson and Brenton FlynnWhy Investors Are Voting Against VIVUSQsymia's launch disappoints the market.
Nov 4, 2012 by Dave WilliamsonWhy Investors Should Be Concerned About DendreonBreaking down Dendreon's Q3 results.
Nov 3, 2012 by Dave WilliamsonWhy Investors Are Excited About Dendreon's EarningsBreaking down the biotech's third-quarter results.
Nov 2, 2012 by Dave WilliamsonVertex's Shocking Decline Hurts InvestorsVertex drops double digits after disappointing quarter
Nov 2, 2012 by Dave WilliamsonDendreon Earnings: Initial ReactionShares are up after reporting third quarter results
Nov 1, 2012 by Dave WilliamsonPfizer Earnings: Critical TakeawaysEverything you need to know in 1 short video.
Nov 1, 2012 by Dave WilliamsonVertex's New Big Pharma PartnersA new potential hep-c drug combo takes shape
Oct 25, 2012 by Dave Williamson3 Health Care Stocks Beating Today’s Market The day's news leaders and market movers.
Oct 24, 2012 by Dave Williamson and Max MacalusoWhy United Therapeutics Is PlungingThe FDA says "no way."
Oct 24, 2012 by Dave Williamson and Max MacalusoWhy These 2 Biotech Stocks Are PlungingUnited Therapeutics and Discovery Labs are down double digits.
Oct 24, 2012 by Dave WilliamsonWhy These 3 Biotech Stocks Are WinningGilead, Amarin, and Cyclacel are all up over 5%
Oct 24, 2012 by Dave WilliamsonWhy Gilead Is SoaringThird quarter earnings may have had something to do with it.
